🇺🇸 FDA
Patent

US 8735400

Compositions and methods for inhibition of the JAK pathway

granted A61KA61K31/155A61K31/506

Quick answer

US patent 8735400 (Compositions and methods for inhibition of the JAK pathway) held by Rigel Pharmaceuticals, Inc. expires Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue May 27 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K31/155, A61K31/506, A61K31/5377, A61K31/538